About
Sublingual Delivery of sedatives
Areas of Focus
Categories
Drug Delivery & FormulationSoutheastern U.S.
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
908
By Phase
PHASE3: 1PHASE2: 1PHASE1: 2
By Status
COMPLETED: 3RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06383273Lead Sponsor
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
PHASE3Recruiting
528 participants
Started: May 1, 2024 · Completed: Jan 31, 2025
NCT05133518Lead Sponsor
A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)
PHASE2Completed
338 participants
Started: Jul 20, 2021 · Completed: Nov 3, 2022
NCT04767035Lead Sponsor
Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine
PHASE1Completed
25 participants
Started: Dec 1, 2020 · Completed: Jan 14, 2021
NCT04485702Lead Sponsor
Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine
PHASE1Completed
17 participants
Started: Jul 20, 2020 · Completed: Aug 29, 2020
Locations (1)
Headquarters
Brentwood, TN, United States
Map
Loading map...